NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 82 resultados LastUpdate Última actualización 29/11/2022 [08:38:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



previousPage Página2 de 4 nextPage   por página


AMPLICON DNA LIBRARY AND KIT FOR ACUTE MYELOID LEUKEMIA GENE PANEL TESTING, AND USE FOR SAME

NºPublicación: WO2022239485A1 17/11/2022

Solicitante:

UNIV HOKKAIDO NAT UNIV CORP [JP]

Resumen de: WO2022239485A1

The present invention provides: an amplicon DNA library which contains a prescribed amplicon for acute myeloid leukemia gene panel testing; a combination which contains a prescribed primer set; an amplicon DNA library preparation kit which contains the primer set combination; a method for producing an amplicon DNA library which uses the primer set combination; and a method for analyzing genetic mutations in a hematopoietic cell of a patient by using the amplicon DNA library.

traducir

VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH AZACITIDINE

NºPublicación: WO2022240786A1 17/11/2022

Solicitante:

ABBVIE INC [US]

Resumen de: WO2022240786A1

The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine for treating myelodysplastic syndromes (MDS).

traducir

VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE

NºPublicación: WO2022240788A1 17/11/2022

Solicitante:

ABBVIE INC [US]

US_2022370481_PA

Resumen de: WO2022240788A1

The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine and a CYP3A inhibitor for treating myelodysplastic syndromes (MDS).

traducir

Methods of using anti-CD79b immunoconjugates

NºPublicación: AU2021259861A1 17/11/2022

Solicitante:

GENENTECH INC

WO_2021217051_A1

Resumen de: AU2021259861A1

Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma and diffuse large B cell lymphoma) using immunoconjugates comprising anti-CD79b antibodies in combination with a Bcl-2 inhibitor (such as venetoclax) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

traducir

Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein

NºPublicación: AU2021251269A1 17/11/2022

Solicitante:

SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
PROVINCIAL HEALTH SERVICES AUTHORITY
UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

WO_2021207709_A1

Resumen de: AU2021251269A1

Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).

traducir

Combined chimeric antigen receptor targeting CD19 and CD20 and applications thereof

NºPublicación: AU2021238330A1 17/11/2022

Solicitante:

CELLULAR BIOMEDICINE GROUP HK LTD

KR_20220145411_PA

Resumen de: AU2021238330A1

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and a scFv targeting CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B- cell lymphoma, leukemia and other diseases.

traducir

Therapeutic treatment for T-cell acute lymphoblastic leukemias using a monoclonal antibody against the pre-T cell receptor

NºPublicación: AU2021257071A1 17/11/2022

Solicitante:

CONSEJO SUPERIOR INVESTIGACION
FUND UNO ENTRE CIEN MIL

ES_2867373_PA

Resumen de: AU2021257071A1

The present invention relates to the treatment of T-cell acute lymphoblastic leukemias (T-ALLs) by means of immunotherapy using a monoclonal antibody that recognises the pre-T cell receptor (pre-TCR) which, owing to its presence at all stages of T-ALL pre-TCR+ development, can also be used as a biomarker for leukaemia-initiating cells (LICs) and as a therapeutic target useful for monitoring minimal residual disease and identifying compounds that inhibit the disease.

traducir

Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof

NºPublicación: AU2021258431A1 17/11/2022

Solicitante:

IOMX THERAPEUTICS AG

TW_202204352_A

Resumen de: AU2021258431A1

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (

traducir

CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY

NºPublicación: US2022363732A1 17/11/2022

Solicitante:

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT [DE]
UNIV BERLIN CHARITE [DE]

CA_3137808_PA

Resumen de: US2022363732A1

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides nucleic acids encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1 or 33, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners.

traducir

USES OF INDOLINONE COMPOUNDS

NºPublicación: US2022362211A1 17/11/2022

Solicitante:

ONCTERNAL THERAPUTICS INC [US]

CN_114569606_PA

Resumen de: US2022362211A1

Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

traducir

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS

NºPublicación: US2022362302A1 17/11/2022

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

US_2022118016_A1

Resumen de: US2022362302A1

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

traducir

1-METHYL-4-(4-PHENYLPHENYL)SULFONYLMETHYLCYCLOHEXYANOL AND 1-METHYL-4-4-(2-PYRIDYL)PHENYLSULFONYLMETHYLCYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE

NºPublicación: US2022363642A1 17/11/2022

Solicitante:

MODERN BIOSCIENCES LTD [GB]

JP_2021534251_A

Resumen de: US2022363642A1

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

traducir

Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof

NºPublicación: US2022362357A1 17/11/2022

Solicitante:

STICHTING RADBOUD UNIV MEDISCH CENTRUM [NL]

CA_3111126_A1

Resumen de: US2022362357A1

Disclosed herein are synergistically effective combinations of Amino Acid Depletion Agents (AADA) and Amino Acid Depletion Agent Sensitizers (AADAS). Also disclosed are methods of using the disclosed combinations to treat subjects with a disease treatable by amino acid depletion-induced cell death (e.g. apoptosis). For example, the disclosed combinations are useful in the treatment or the manufacture of a medicament for use in the treatment of adult and pediatric cancers, in particular, acute lymphoblastic leukemia (ALL), as well as other conditions where amino acid depletion-induced apoptosis is expected to have a therapeutically useful effect. The synergistic combinations are also effective against solid tumors and lymphomas, including gastric cancer, pancreatic cancer, NK lymphoma, DLBCL, colorectal cancer, bladder cancer, hepatic cancer and glioblastoma.

traducir

CERAMIDE RATIOS AS PREDICTIVE AND THERAPEUTIC BIOMARKERS FOR LEUKEMIAS

NºPublicación: US2022362177A1 17/11/2022

Solicitante:

UNIV VIRGINIA PATENT FOUNDATION [US]

WO_2021076985_A1

Resumen de: US2022362177A1

Provided are methods for treating diseases, disorders, and conditions associated with undesirable cellular proliferation in subjects in need thereof. In some embodiments, the methods include administering to a subject in need thereof a therapeutically effective amount of a composition comprising, consisting essentially of, or consisting of a chemotherapeutic agent and a short chain ceramide. Also provided are methods for increasing total ceramide levels in cells, for increasing long chain ceramide to a very long chain ceramide ratios in cells, methods for enhancing apoptosis of cells, for prognosing subjects with diseases, disorders, and conditions associated with undesirable cellular proliferation with respect to treatments, for increasing sensitivities of drug-resistant tumor and/or cancer cells to chemotherapeutics, and compositions that have one or more short chain ceramides and one or more chemotherapeutically active agents.

traducir

ADMINISTRATION REGIMES OF CANNABINOIDS IN COMBINATION WITH CHEMOTHERAPEUTICS AGAINST CANCER

NºPublicación: US2022362168A1 17/11/2022

Solicitante:

JAY PHARMA INC [CA]

WO_2021028646_A1

Resumen de: US2022362168A1

The present invention in the field of cancer therapeutics is based on the finding that when cannabinoids are administered to cancer subjects after a chemotherapeutic agent has been administered, the combined treatment leads to increased survival prognosis, a reduction in disease progression, stabilisation of disease state and inhibition of tumour growth than administration of the chemotherapeutic agent alone. There is provided a pharmaceutical composition comprising a chemotherapeutic agent for use in the treatment of bladder, brain and spinal cord, colorectal, head and neck, lung, lymphoma, neuroendocrine, oesophageal, ovarian, pancreatic and prostate cancer, wherein said treatment comprises a first phase in which the chemotherapeutic agent is administered, and a subsequent second phase in which a cannabinoid is administered.

traducir

METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE

NºPublicación: US2022362255A1 17/11/2022

Solicitante:

CELGENE CORP [US]
BRISTOL MYERS SQUIBB CO [US]

Resumen de: US2022362255A1

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.

traducir

DOSING REGIMENS FOR CANCER IMMUNOTHERAPY

NºPublicación: WO2022241036A1 17/11/2022

Solicitante:

NKARTA INC [US]

Resumen de: WO2022241036A1

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer.

traducir

METHODS AND MATERIALS FOR TREATING CANCER

NºPublicación: WO2022240583A1 17/11/2022

Solicitante:

MAYO FOUND MEDICAL EDUCATION & RES [US]

Resumen de: WO2022240583A1

This document provides methods and materials for treating a mammal (e.g., a human) having cancer (e.g., a central nervous system (CNS) cancer such as a latent CNS cancer). For example, one or more inhibitors of a B-cell lymphoma-extra large (Bcl-xL) polypeptide can be administered to a mammal (e.g., a human) having a CNS cancer to treat the mammal.

traducir

COMBINATIONS FOR TREATMENT OF CANCER

NºPublicación: WO2022241122A1 17/11/2022

Solicitante:

SYNDAX PHARMACEUTICALS INC [US]
UNIV TEXAS [US]

Resumen de: WO2022241122A1

The present disclosure is directed to combinations of menin inhibitors and Bcl-2 inhibitors, optionally in further combination with hypomethylating agents and/or FLT3 inhibitors for the treatment of cancer. Specifically, menin inhibitors combined with venetoclax are synergistic in the treatment of cancers with a HOX gene signature such as acute myeloid leukemia.

traducir

COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING CANCER

NºPublicación: WO2022241095A1 17/11/2022

Solicitante:

AYALA PHARMACEUTICALS INC [US]

Resumen de: WO2022241095A1

The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof in combination with a composition comprising one or more B-cell leukemia/lymphoma-2 (Bcl-2) family inhibitors. The present invention also provides methods of treating, suppressing, or inhibiting a hyperproliferative disorder or inhibiting tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof and a second composition comprising one or more Bcl-2 family inhibitors.

traducir

METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

NºPublicación: WO2022241430A1 17/11/2022

Solicitante:

JANSSEN BIOTECH INC [US]

US_2022373550_PA

Resumen de: WO2022241430A1

Methods of monitoring progression of multiple myeloma or plasmacytoma, particularly relapsed or refractory multiple myeloma, are described. Also described are methods of treating or determining response to a treatment for multiple myeloma or plasmacytoma in a subject.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS

NºPublicación: US2022354842A1 10/11/2022

Solicitante:

HANMI PHARM IND CO LTD [KR]

JP_2022538817_PA

Resumen de: US2022354842A1

Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

traducir

PRODUCTION METHOD FOR CEREBRAL ORGANOID

NºPublicación: US2022356443A1 10/11/2022

Solicitante:

UNIV KEIO [JP]

CN_114026222_A

Resumen de: US2022356443A1

A production method for a cerebral organoid having amyloid plaques is provided, the method including a step (a) of forming, in the presence of a SMAD inhibitor, an embryoid body from a pluripotent stem cell having a mutation in an Alzheimer's disease-related gene; a step (b) of embedding the embryoid body after the step (a) in an extracellular matrix and three-dimensionally culturing the embedded embryoid body in the presence of a SMAD inhibitor and a glycogen synthase kinase 3β (GSK3β) inhibitor to form an organoid; and a step (c) of removing the organoid after the step (b) from the extracellular matrix and subjecting the removed organoid to stirring culture in a medium, where at least a part of the step (c) is carried out in the presence of leukemia inhibitory factor (LIF).

traducir

Stable ready to dilute formulations of carfilzomib

NºPublicación: AU2021256189A1 10/11/2022

Solicitante:

KASHIV BIOSCIENCES LLC

Resumen de: AU2021256189A1

The invention provides room temperature stable ready to dilute injectable formulation comprising carfilzomib or it pharmaceutically acceptable derivatives. The invention further provides methods for treating patients with multiple myeloma by administering room temperature stable ready to dilute injectable formulations comprising carfilzomib or its pharmaceutically acceptable derivatives.

traducir

Novel tumor-specific antigens for acute myeloid leukemia (AML) and uses thereof

Nº publicación: AU2021256477A1 10/11/2022

Solicitante:

UNIV MONTREAL

CN_115397842_PA

Resumen de: AU2021256477A1

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as AML is also described.

traducir

previousPage Página2 de 4 nextPage por página

punteroimgVolver